Vascular endothelial growth factor is essential for corpus luteum angiogenesis

Nature Medicine

Volumn 4, Issue 3, 1998, Pages 336-340

  Ferrara, Napoleone ^a   Chen, Helen ^a   Davis Smyth, Terri ^a   Gerber, Hans Peter ^a   Nguyen, Thuy Nhung ^a   Peers, David ^a   Chisholm, Vanessa ^a   Hillan, Kenneth J ^a   Schwall, Ralph H ^a  

^a GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VASCULOTROPIN;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORPUS LUTEUM; FEMALE; FEMALE FERTILITY; HORMONAL REGULATION; MOUSE; NONHUMAN; PREGNANCY; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

ANIMALS; CORPUS LUTEUM; ENDOTHELIAL GROWTH FACTORS; FEMALE; GONADOTROPINS; IN SITU HYBRIDIZATION, FLUORESCENCE; LYMPHOKINES; NEOVASCULARIZATION, PHYSIOLOGIC; PROTO-ONCOGENE PROTEINS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTORS, GROWTH FACTOR; UTERUS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1; VASCULAR ENDOTHELIAL GROWTH FACTORS;

ANIMALIA;

EID: 0031940839     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/nm0398-336     Document Type: Article

References (25)

1. Bassett, D.E.L. The changes in the vascular pattern of the ovary of the albino rat during the estrous cycle. Am. J. Anat. 73, 251-278 (1943).
2. Gospodarowicz, D. & Takral, T.K. Production of a corpus luteum angiogenic factor responsible for proliferation of capillaries and neovascularization of the corpus luteum. Proc. Natl. Acad. Sci. USA 75, 847-851 (1978).
3. Ferrara, N. & Davis-Smyth, T. The biology of vascular endothelial growth factor Endocr. Rev. 18, 4-25 (1997).
4. Phillips, H.S., Hains, J., Leung, D.W. & Ferrara, N. Vascular endothelial growth factor is expressed in rat corpus luteum. Endocrinology 127, 965-967 (1990).
5. Kamat, B.R., Brown, L.F., Manseau, E.J., Senger, D.R. & Dvorak, H.F. Expression of vascular permeability factor/vascular endothelial growth factor by human granulosa and theca lutein cells: Role in corpus luteum development. Am. J. Pathol. 146, 157-165 (1995).
6. Shweiki, D., Itin, A., Neufeld, G., Gitay-Goren, H. & Keshet, E, Patterns of expression of vascular endothelial growth factor (VEGF) and VEGF receptors in mice suggest a role in hormonally-mediated angiogenesis. J. Clin. Invest. 91, 2235-2243 (1993).
7. Gospodarowicz, D., Cheng, J., Lui, G.M., Baird, A. & Bohlen, P. Corpus luteum angiogenesis factor is related to fibroblast growth factor. Endocrinology 117, 2283-2290 (1985).
8. Maisonpierre, P.C. et al. Angiopoietin-2, a natural antagonist for Tie-2 that disrupts in vivo angiogenesis. Science 277, 55-60 (1997).
9. de Vries, C. et al. The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science 255, 989-991 (1992).
10. Aiello, L.P. et al. Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. Proc Natl. Acad. Sci USA 92, 10457-10461 (1995).
11. Kendall, R.L., Wang, G. & Thomas, K.A. Identification of a natural soluble form of the vascular endothelial growth factor receptor, FLT-1, and its heterodimerization with KDR. Biochem. Biophys. Res. Commun. 226, 324-328 (1996).
12. Davis-Smyth, T., Chen, H., Park, J., Presta, L.G. & Ferrara, N. The second immunoglobulin-like domain of the VEGF tyrosine kinase receptor Flt-1 determines ligand binding and may initiate a signal transduction cascade. EMBO J. 15, 4919-4927 (1996).
13. Gates, A.H. Maximizing yield and developmental uniformity of eggs. in Methods in Mammalian Embryology. (ed. Daniels, J.) 46-76 (Freeman, San Francisco, 1971).
14. Rothchild, I. The regulation of the mammalian corpus luteum. Rec. Prog. Horm. Res. 37, 183-298 (1981).
15. Park, J.E., Chen, H.H., Winer, J., Houck, K.A. & Ferrara, N. Placenta growth factor: Potentiation of vascular endothelial growth factor bioactivity, in vitro and in vivo, and high affinity binding to Flt-1 but not to Flk-1/KDR. J. Biol. Chem. 269, 25646-25654 (1994).
16. Cao, Y. et al. Heterodimers of placenta growth factor/vascular endothelial growth factor: Endothelial activity, tumor cell expression, and high affinity binding to Flk-1/KDR J. Biol. Chem. 271, 3154-3162 (1996).
17. Smith, L.E. et al. Essential role of growth hormone in ischemia-induced retinal neovascularization. Science 276, 1706-1709 (1997).
18. Goldziher, J.W. & Green, J.A. The polycystic ovary. I. Clinical and histologic features. J. Clin. Endocrinol. Metab. 22, 325-332 (1962).
19. Engel, T., Jewelewicz, R., Dyrenfurth, I., Speroff, L. & Vande Wiele, R.L. Ovarian hyperstimulation syndrome: Report of one case with notes on pathogenesis and treatment Am. J. Obstet. Gynecol. 112, 1052-1057 (1972).
20. McClure, N. et al. Vascular endothelial growth factor as a capillary permeability agent in ovarian hyperstimulation syndrome. Lancet 344, 235-269 (1994).
21. Murthy, Y.S., Arronet, C.H. & Pareck, M.C. Luteal phase inadequacy. Obstet. Gynecol. 36, 758-772 (1970).
22. Capon, D.J. et al. Designing CD4 immunoadhesins for AIDS therapy. Nature 337, 525-531 (1989).
23. Finnerty, H. et al. Molecular cloning of murine FIT and FLT4. Oncogene 8, 2293-2298 (1993).
24. Lucas, B.K. et al. High-level production of recombinant proteins using dicistronic DHFR into expression vector. Nucleic Add Res. 24, 1774-1779 (1996).
25. Chisholm, V. High efficiency gene transfer into mammalian cells. in DNA Cloning 4: A Practical Approach, Mammalian systems, (eds. Glover, D.M. & Harnes, B.D.) 1-39 (Oxford University Press, New York 1995).